Nov 01, 2010
Pharmaceutical Speaker Programs provides innovative, actionable strategies and best practices that will make your speaker events more effective and generate better ROI. Our data benchmarks - developed from input from marketing executives
Nov 01, 2010
Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity.
Nov 01, 2010
Chart the future of the global oncology market Explore the fiercely competitive oncology market with the most comprehensive resource available. Augment or build your models with deep, meticulously researched data - and expand
Nov 01, 2010
Diabetes Market Forecast to 2015 provides teams with an in-depth analysis of the global diabetes market. Analysts place critical drug information in a relevant industrywide context. Our study details marketed brands, pipeline products
Oct 30, 2010
Guarantee smooth approvals with a top-flight regulatory affairs team Regulatory teams save time and money as they drive commercial and development goals forward. Build healthy relationships with - and receive clear direction from - regulatory
Oct 30, 2010
This is a one-of-a-kind study dedicated exclusively to drug safety and pharmacovigilance. Benchmarking Drug Safety and Pharmacovigilance is a data-driven guide to optimizing your company's drug safety efforts.
Oct 30, 2010
Gain instant access to detailed benchmarks and best practices that will streamline your health economics strategy. This one-of-a-kind study showcases the most up-to-date information on health economics and outcomes research (HEOR) goals
Oct 30, 2010
This data-rich benchmarking study focuses exclusively on the nuts and bolts of successful Medical Science Liaison (MSL) group management: • MSL team structure • Team sizing • Resource and budget allocation • Activity breakdowns
Oct 30, 2010
Clinical trial costs are skyrocketing amidst patient shortages, fewer drug approvals and limited growth in the number of available clinical investigators. At the same time, companies face stringent demands for more safety data — and patient
Oct 30, 2010
This section report focuses on the attitudes and associations the American, Canadian and English public has about climate change - and the emotions the subject provokes. The data is analysed by key demographics across each country